Small study tests rituximab against rare vessel disease

NCT ID NCT03920722

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug rituximab, given with steroids, works better than steroids alone for people with a rare disease called microscopic polyangiitis that inflames small blood vessels. Only 8 patients took part, and the goal was to see if the combination could prevent relapses. Because the study is so small, the results are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rituximab

What this could lead to

If successful, this could point toward a more effective treatment for microscopic polyangiitis, reducing relapses.

What could go wrong

This is a very small, completed phase 3 trial with only 8 participants, so results may not apply broadly. Rituximab can cause infusion reactions and increase infection risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS (MPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis microscopic polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cochin Hospital

    Paris, 75014, France